{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:05:57Z","timestamp":1742378757094},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Respir Care Rep"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s13665-013-0064-y","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T03:11:48Z","timestamp":1383102708000},"page":"199-207","source":"Crossref","is-referenced-by-count":14,"title":["Diagnosis and treatment of latent tuberculosis infection: an update"],"prefix":"10.1007","volume":"2","author":[{"given":"Anna K.","family":"Person","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April C.","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"issue":"4","key":"64_CR1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJM199201233260404","volume":"326","author":"CL Daley","year":"1992","unstructured":"Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326(4):231\u20135.","journal-title":"N Engl J Med"},{"issue":"7","key":"64_CR2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","volume":"282","author":"C Dye","year":"1999","unstructured":"Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677\u201386.","journal-title":"JAMA"},{"issue":"3","key":"64_CR3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","volume":"177","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999\u20132000. Am J Respir Crit Care Med. 2008;177(3):348\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"64_CR4","volume":"2","author":"MJ Smieja","year":"2000","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2, CD001363.","journal-title":"Cochrane Database Syst Rev"},{"key":"64_CR5","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000. pages S221\u201347.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"64_CR6","unstructured":"Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010. pages 1\u201325."},{"key":"64_CR7","doi-asserted-by":"crossref","unstructured":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000. pages 1376\u201395.","DOI":"10.1164\/ajrccm.161.4.16141"},{"issue":"2","key":"64_CR8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.281.2.169","volume":"281","author":"ME Villarino","year":"1999","unstructured":"Villarino ME, Burman W, Wang YC, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA. 1999;281(2):169\u201371.","journal-title":"JAMA"},{"issue":"21","key":"64_CR9","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1001\/jama.283.21.2793","volume":"283","author":"HM Blumberg","year":"2000","unstructured":"Blumberg HM, White N, Parrott P, et al. False-positive tuberculin skin test results among health care workers. JAMA. 2000;283(21):2793.","journal-title":"JAMA"},{"issue":"10","key":"64_CR10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajic.2006.05.288","volume":"34","author":"KA Gillenwater","year":"2006","unstructured":"Gillenwater KA, Sapp SC, Pearce K, et al. Increase in tuberculin skin test converters among health care workers after a change from Tubersol to Aplisol. Am J Infect Control. 2006;34(10):651\u20134.","journal-title":"Am J Infect Control"},{"issue":"1","key":"64_CR11","first-page":"93","volume":"7","author":"JC Grabau","year":"2003","unstructured":"Grabau JC, Hughes SE, Foster EA, et al. False-positive tuberculin skin tests in a state prison system. Int J Tuberc Lung Dis. 2003;7(1):93\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"64_CR12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/CVI.00375-08","volume":"16","author":"SR Mehta","year":"2009","unstructured":"Mehta SR, MacGruder C, Looney D, et al. Differences in tuberculin reactivity as determined in a veterans administration employee health screening program. Clin Vaccine Immunol. 2009;16(4):541\u20133.","journal-title":"Clin Vaccine Immunol"},{"issue":"16","key":"64_CR13","first-page":"312","volume":"62","author":"Centers for Disease Control and Prevention CDC","year":"2013","unstructured":"Centers for Disease Control and Prevention CDC. National shortage of purified-protein derivative tuberculin products. MMWR Morb Mortal Wkly Rep. 2013;62(16):312.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"64_CR14","unstructured":"Jensen PA, Lambert LA, Iademarco MF, et al. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005. pages 1\u2013141."},{"key":"64_CR15","unstructured":"QuantiFERON Gold TB In-Tube package insert. [Internet]. 2013 [cited 2013 Jul 12]. Available from: http:\/\/www.cellestis.com\/IRM\/Company\/ShowPage.aspx?CPID=1171 ."},{"key":"64_CR16","unstructured":"T Spot.TB package insert. [Internet]. 2013 [cited 2013 Jul 9]. Available from: http:\/\/www.oxfordimmunotec.com\/Technical_Documents_North_America ."},{"issue":"1","key":"64_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1378\/chest.11-3157","volume":"142","author":"R Diel","year":"2012","unstructured":"\u2022\u2022 Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-\u03b3 release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest. 2012;142(1):63\u201375. Meta-analysis of 28 studies evaluating PPV or NPV for progression to active TB. Excluded those who had received preventive therapy. For high-risk individuals in particular, there was a suggestion of higher PPV for the IGRAs evaluated compared with TST.","journal-title":"Chest"},{"issue":"1","key":"64_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"\u2022 Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-\u03b3 release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45\u201355. This was a systematic review and meta-analysis assessing the ability of IGRAs and TST to predict development of active TB. Those who had taken preventive therapy were not excluded and several \u201cin-house\u201d IGRAs were included. When positive IGRAs were compared with positive TSTs, only modest, non-significant differences in IRR for incident tuberculosis were seen.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"64_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.200604-472OC","volume":"174","author":"M Pai","year":"2006","unstructured":"Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006;174(3):349\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"64_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","volume":"146","author":"D Menzies","year":"2007","unstructured":"Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146(5):340\u201354.","journal-title":"Ann Intern Med"},{"issue":"1","key":"64_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.11-0992","volume":"142","author":"KS Fong","year":"2012","unstructured":"\u2022\u2022 Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-\u03b3 release assay conversions in serial testing of health-care workers in a TB control program. Chest. 2012;142(1):55\u201362. Retrospective chart review of health-care workers receiving QuantiFERON Gold In-Tube testing for screening at a US hospital. Several health care workers with no known TB exposure found to have low-positive IGRA results; several later had reversion. Reveals how a single \u201ccut-point\u201d for positivity on serial testing may lead to conversions and\/or reversions of unclear clinical significance.","journal-title":"Chest"},{"issue":"6","key":"64_CR22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1378\/chest.11-3299","volume":"142","author":"JS Park","year":"2012","unstructured":"\u2022 Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-\u03b3 release assays among health-care workers in contact with patients with TB. Chest. 2012;142(6):1461\u20138. Study of 49 healthcare workers in S. Korea who were contacts with patients with active TB. They were followed for one year with monthly QuantiFERON TB Gold In-Tube assays. Frequent fluctuations around the single \u201ccut-point\u201d were seen; 52 % had conversions and\/or reversions when a single cut-point of 0.35 IU mL \u22121 was used. Demonstrates difficulty in interpreting test with a single cut-point when used serially.","journal-title":"Chest"},{"issue":"2","key":"64_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5588\/ijtld.11.0364","volume":"16","author":"S Rafiza","year":"2012","unstructured":"Rafiza S, Rampal KG. Serial testing of Malaysian health care workers with QuantiFERON\u00ae-TB Gold In-Tube. Int J Tuberc Lung Dis. 2012;16(2):163\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"64_CR24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1745-6673-7-6","volume":"7","author":"FC Ringshausen","year":"2012","unstructured":"Ringshausen FC, Schablon A, Nienhaus A. Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. J Occup Med Toxicol. 2012;7(1):6.","journal-title":"J Occup Med Toxicol"},{"issue":"1","key":"64_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/thx.2010.143180","volume":"67","author":"A Zwerling","year":"2012","unstructured":"Zwerling A, van den Hof S, Scholten J, et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax. 2012;67(1):62\u201370.","journal-title":"Thorax"},{"issue":"6","key":"64_CR26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1378\/chest.12-1208","volume":"142","author":"M Pai","year":"2012","unstructured":"Pai M. Serial testing with TB interferon-\u03b3 release assays: toward a nuanced understanding. Chest. 2012;142(6):1366\u20137.","journal-title":"Chest"},{"issue":"6","key":"64_CR27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/670635","volume":"34","author":"CL Daley","year":"2013","unstructured":"Daley CL, Reves RR, Beard MA, et al. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-\u03b3 release assay testing. Infect Control Hosp Epidemiol. 2013;34(6):625\u201330.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"64_CR28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.12-0045","volume":"142","author":"R Loddenkemper","year":"2012","unstructured":"Loddenkemper R, Diel R, Nienhaus A. To repeat or not to repeat-that is the question: serial testing of health-care workers for TB infection. Chest. 2012;142(1):10\u20131.","journal-title":"Chest"},{"key":"64_CR29","first-page":"601737","volume":"2013","author":"A Trajman","year":"2013","unstructured":"Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013;2013:601737.","journal-title":"Pulm Med"},{"issue":"3","key":"64_CR30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M. Systematic review: T-cell\u2013based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177.","journal-title":"Ann Intern Med"},{"key":"64_CR31","unstructured":"Garrett D, Katz D, Chideya S. Prospective comparison of the tuberculin skin test and interferon gamma release assays in diagnosing infection with mycobacterium tuberculosis and in predicting progression to tuberculosis. [Internet]. 2013 [cited 2013 Jul 14]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01622140 NLM"},{"issue":"4","key":"64_CR32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.201107-1244OC","volume":"185","author":"JD Mancuso","year":"2012","unstructured":"\u2022\u2022 Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012;185(4):427\u201334. US military recruits received simultaneous testing with QuantiFERON-TB Gold In-Tube, T-SPOT.TB, and TST. No differences were seen in specificities among the three tests and 77 % of those with a positive test were positive for one test only. The lower the risk of TB, the lower the quantitative results on IGRA testing and the more likely just one test would be positive.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"64_CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1471-2458-13-353","volume":"13","author":"G Gran","year":"2013","unstructured":"Gran G, A\u00dfmus J, Dyrhol-Riise AM. Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results. BMC Public Health. 2013;13(1):353.","journal-title":"BMC Public Health"},{"issue":"8","key":"64_CR34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.5588\/ijtld.10.0650","volume":"15","author":"P Weinfurter","year":"2011","unstructured":"Weinfurter P, Blumberg HM, Goldbaum G, et al. Predictors of discordant tuberculin skin test and QuantiFERON\u00ae-TB Gold In-Tube results in various high-risk groups. Int J Tuberc Lung Dis. 2011;15(8):1056\u201361.","journal-title":"Int J Tuberc Lung Dis"},{"key":"64_CR35","first-page":"1650","volume":"60","author":"Centers for Disease Control and Prevention CDC","year":"2011","unstructured":"Centers for Disease Control and Prevention CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"64_CR36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"\u2022 Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320. Conducted among HIV-infected persons in South Africa, this study revealed no significant difference in the protective effect of four regimens: three months of once-weekly isoniazid\u2009+\u2009rifapentine (directly observed), three months of twice-weekly isoniazid\u2009+\u2009rifampin (directly observed), six months of daily isoniazid (self-administered), and up to six years of daily isoniazid (self-administered). Continuous isoniazid was poorly tolerated.","journal-title":"N Engl J Med"},{"issue":"23","key":"64_CR37","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"\u2022\u2022 Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366. This study conducted in low and medium tuberculosis-incidence countries revealed that three months of once-weekly isoniazid\u2009+\u2009rifapentine (directly observed) was at least as effective as nine months of daily isoniazid (self-administered). The tolerability of both regimens was similar.","journal-title":"N Engl J Med"},{"key":"64_CR38","unstructured":"Villarino ME, Scott N, Weis S, et al. Tolerability among children of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection. IMPAACT and the TB Trials Consortium. October 20, 2012, San Diego, CA, Presentation # 1323. Presented at IDWeek 2012, a Joint Meeting of IDSA, SHEA, HIVMA, and PIDS."},{"key":"64_CR39","unstructured":"Sterling TR, Benson CA, Shang N, et al. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection. AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Presented at the International AIDS Society Conference. July 2012. Washington, DC."},{"key":"64_CR40","unstructured":"Presented at the International Union Against TB and Lung Disease International Conference. November 2012."},{"issue":"2","key":"64_CR41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002030-200101260-00011","volume":"15","author":"MA Quigley","year":"2001","unstructured":"Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15(2):215\u201322.","journal-title":"AIDS"},{"issue":"16","key":"64_CR42","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","volume":"15","author":"JL Johnson","year":"2001","unstructured":"Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15(16):2137\u201347.","journal-title":"AIDS"},{"issue":"9777","key":"64_CR43","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"\u2022 Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398. This was a study of the effect of prolonged isoniazid treatment among HIV-infected persons in Botswana (an area of high risk for M. tuberculosis re-infection). Among TST-positive persons the risk of mortality was a factor of three lower for those who received 36INH compared with 6INH.","journal-title":"Lancet"},{"key":"64_CR44","unstructured":"World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO. 2011."},{"issue":"20","key":"64_CR45","first-page":"398","volume":"62","author":"Centers for Disease Control and Prevention CDC","year":"2013","unstructured":"Centers for Disease Control and Prevention CDC. Impact of a shortage of first-line antituberculosis medication on tuberculosis control - United States, 2012\u20132013. MMWR Morb Mortal Wkly Rep. 2013;62(20):398\u2013400.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Current Respiratory Care Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13665-013-0064-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13665-013-0064-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13665-013-0064-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T13:58:30Z","timestamp":1564581510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13665-013-0064-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s13665-013-0064-y","relation":{},"ISSN":["2161-332X"],"issn-type":[{"value":"2161-332X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}